Immix Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Immix Biopharma
IMMX Stock  USD 2.11  0.14  7.11%   
Immix Biopharma financial statements provide useful quarterly and yearly information to potential Immix Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immix Biopharma financial statements helps investors assess Immix Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immix Biopharma's valuation are summarized below:
Market Capitalization
54.2 M
Earnings Share
(0.84)
We have found one hundred twenty available fundamental trends for Immix Biopharma, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immix Biopharma regular market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 28.2 M in 2024. Enterprise Value is likely to rise to about 28.8 M in 2024
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 360.6 K or Depreciation And Amortization of 3 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.68 or Book Value Per Share of 0.98. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Immix Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12 M19.9 M5 M
Slightly volatile
Short and Long Term Debt Total42.8 K45 K3 M
Slightly volatile
Other Current Liabilities2.4 M2.3 M611.1 K
Slightly volatile
Total Current Liabilities2.4 M3.7 M3.9 M
Slightly volatile
Property Plant And Equipment Net52.7 K50.2 K14.4 K
Slightly volatile
Accounts Payable1.5 M1.4 M396.8 K
Slightly volatile
Cash10.9 M17.5 M4.5 M
Slightly volatile
Non Current Assets Total144.3 K137.4 K26.8 K
Slightly volatile
Cash And Short Term Investments10.9 M17.5 M4.5 M
Slightly volatile
Net Receivables1.2 M1.2 M304.6 K
Slightly volatile
Common Stock Shares Outstanding13.1 M17.3 M9.5 M
Slightly volatile
Liabilities And Stockholders Equity12 M19.9 M5 M
Slightly volatile
Other Current Assets630.2 K1.1 M247.1 K
Slightly volatile
Other Stockholder Equity37.3 M69.7 M14.1 M
Slightly volatile
Total Liabilities2.5 M3.7 M4 M
Slightly volatile
Property Plant And Equipment Gross52.7 K50.2 K14.4 K
Slightly volatile
Short and Long Term Debt42.8 K45 K3 M
Slightly volatile
Total Current Assets12 M19.8 M5 M
Slightly volatile
Accumulated Other Comprehensive Income120.4 K134.7 K85.4 K
Slightly volatile
Capital Stock1.2 K2 K642
Slightly volatile
Short Term Debt42.8 K45 K3 M
Slightly volatile
Common Stock1.2 K2 K642
Slightly volatile
Property Plant Equipment5.3 K3.2 K8.1 K
Slightly volatile
Current Deferred Revenue274.3 K308.6 K336 K
Slightly volatile
Other Liabilities380 K427.5 K465.5 K
Slightly volatile

Immix Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision12.5 K23.6 K18.4 K
Slightly volatile
Depreciation And Amortization3 K5.5 K1.9 K
Slightly volatile
Selling General Administrative7.8 M7.4 M1.5 M
Slightly volatile
Other Operating Expenses16.9 M16.1 M3.4 M
Slightly volatile
Research Development9.2 M8.7 M1.9 M
Slightly volatile
Cost Of Revenue3 K5.5 K1.7 K
Slightly volatile
Total Operating Expenses16.9 M16.1 M3.4 M
Slightly volatile
Reconciled Depreciation2.4 K3 K1.5 K
Slightly volatile
Income Tax Expense17.8 K26.4 K18.9 K
Slightly volatile
Selling And Marketing Expenses5.2 K5.8 K6.3 K
Slightly volatile

Immix Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.2 M13.4 M2.9 M
Slightly volatile
Depreciation3 K5.5 K1.7 K
Slightly volatile
Total Cash From Financing Activities12.6 M15.5 M5.3 M
Slightly volatile
End Period Cash Flow10.9 M17.5 M4.5 M
Slightly volatile
Change To Netincome681.8 K717.7 K2.1 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation4.438.576.0478
Pretty Stable
Payables Turnover0.00360.00380.0062
Slightly volatile
Cash Per Share0.581.00970.411
Slightly volatile
Days Payables Outstanding100.4 K95.7 K74.4 K
Slightly volatile
Income Quality0.460.72910.7085
Slightly volatile
Current Ratio5.055.31677.6144
Slightly volatile
Graham Number3.144.35153.1084
Slightly volatile
Capex Per Share0.00140.00270.0019
Pretty Stable
Average Receivables112.6 K126.6 K137.9 K
Slightly volatile
Interest Debt Per Share0.00.00.8688
Slightly volatile
Debt To Assets0.0030.00323.4061
Slightly volatile
Days Of Payables Outstanding100.4 K95.7 K74.4 K
Slightly volatile
Pretax Profit Margin0.07340.08260.09
Slightly volatile
Ebt Per Ebit0.920.96462.3139
Pretty Stable
Operating Profit Margin0.07340.08260.09
Slightly volatile
Ebit Per Revenue0.07340.08260.09
Slightly volatile
Quick Ratio5.055.31677.6144
Slightly volatile
Net Income Per E B T1.110.99081.0222
Pretty Stable
Cash Ratio4.474.70477.2489
Slightly volatile
Operating Cash Flow Sales Ratio0.06620.07450.0811
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.161.0239
Slightly volatile
Debt Ratio0.0030.00323.4061
Slightly volatile
Net Profit Margin0.07350.08270.0901
Slightly volatile
Gross Profit Margin0.80.90.98
Slightly volatile

Immix Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap28.2 M27.3 M29.8 M
Pretty Stable
Enterprise Value28.8 M19.4 M29.9 M
Slightly volatile

Immix Fundamental Market Drivers

Cash And Short Term Investments17.5 M

Immix Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue308.6 K274.3 K
Cost Of Revenue5.5 K3 K
Stock Based Compensation To Revenue(0.01)(0.01)
Sales General And Administrative To Revenue(0.04)(0.04)
Research And Ddevelopement To Revenue(0.04)(0.04)
Revenue Per Share(6.09)(6.39)
Ebit Per Revenue 0.08  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY